MONTEVIDEO, Uruguay, Nov. 12, 2018 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 3Q18 and 9M18.
HIGHLIGHTS
Net revenues for 3Q18 increased by 2% in constant currency, also impacted by discontinued business and SOLVADI®, marking BRL 829M LTM (including hyperinflation adjustment).
Gross profit rose by 16% vs. 3Q17, in constant currency.
Gross margin of 51% (including hyperinflation adjustments) vs. 50% in 3Q17.
Adjusted EBITDA grew by 34% in constant currency vs. 3Q17.
Adjusted EBITDA margin came to 24% in 3Q18 (including hyperinflation adjustment), improving 283 bps vs. 3Q17.
Net income totaled BRL 13M in 3Q18 (including hyperinflation adjustment) from a loss of BRL 8M in 3Q17.
Adjusted net income up 82% from 3Q17, in constant currency.
Launches of new products continue to be main focus.
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community. Aspire Health experienced a data security incident that may have involved personal and...
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...
